James Marks, MD, PhD
Professor Emeritus
Anesthesia
School of Medicine

Education & Training

Show all (2) Hide

• M.D. School of Medicine University of California, San Francisco 1979
• Residency School of Medicine University of California, San Francisco

Websites

Show all (1) Hide

• Profile at UCSF Cancer Center (cancer.ucsf.edu)

Grants and Projects

Show all (10) Hide

• Antibody Research Technology Center, NIH, 2014-2019
• Generation of therapeutic antibodies to serotype F botulism, NIH, 2013-2019
• Trispecific monoclonal antibody for botulinum neurotoxin intoxication therapy, NIH, 2012-2018
• Bio-Organic Biomedical Mass Spectrometry Resource, NIH, 1982-2015
• Pacific Southwest RCE for Biodefense & Emerging Infectious Diseases Research, NIH, 2005-2015
• Trispecific monoclonal antibody for botulinum neurotoxin intoxication therapy, NIH, 2012-2014
• Development of botulinum neurotoxin immunotherapy, serotypes C, D, F, and G, NIH, 2007-2013
• Development of botulinum neurotoxin immunotherapy, NIH, 2003-2008
• Mechanism-Based Evaluations of ErbB-Targeted Agents, NIH, 2001-2008
• Deciphering toxin neutralization by oligoclonal antibody, NIH, 2002-2005

Publications (214)

Top publication keywords:
AntitoxinsSingle-Chain AntibodiesImmunoglobulin FragmentsAntibodies, NeoplasmPeptide LibraryClostridium botulinumBotulinum Toxins, Type AAntibodies, BacterialAntibody AffinityImmunoglobulin Variable RegionEpitopesBotulinum ToxinsBotulismAntibodies, MonoclonalAntibody Specificity

• Single Tri-Epitopic Antibodies (TeAbs) to Botulinum Neurotoxin Serotypes B, E, and F Recapitulate the Full Potency of a Combination of Three Monoclonal Antibodies in Toxin Neutralization.
  Toxins 2025 Lou J, Wen WH, Conrad F, Tam CC, Garcia-Rodriguez C, Farr-Jones S, Marks JD
• Dynamic allostery drives autocrine and paracrine TGF-β signaling.
  Cell 2024 Jin M, Seed RI, Cai G, Shing T, Wang L, Ito S, Cormier A, Wankowicz SA, Jespersen JM, Baron JL, Carey ND, Campbell MG, Yu Z, Tang PK, Cossio P, Wen W, Lou J, Marks J, Nishimura SL, Cheng Y
• Predictors of All-Cause 30-Day Readmissions in Patients with Heart Failure at an Urban Safety Net Hospital: The Importance of Social Determinants of Health and Mental Health.
  American journal of medicine open 2023 Steverson AB, Marano PJ, Chen C, Ma Y, Stern RJ, Feng J, Gennatas ED, Marks JD, Durstenfeld MS, Davis JD, Hsue PY, Zier LS
• San Francisco's Citywide COVID-19 Response: Strategies to Reduce COVID-19 Severity and Health Disparities, March 2020 Through May 2022.
  Public health reports (Washington, D.C. : 1974) 2023 Sachdev DD, Petersen M, Havlir DV, Schwab J, Enanoria WTA, Nguyen TQ, Mercer MP, Scheer S, Bennett A, Tenner AG, Marks JD, Bobba N, Philip S, Colfax G
• A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice.
  Toxins 2023 Fan Y, Lou J, Tam CC, Wen W, Conrad F, Leal da Silva Alves P, Cheng LW, Garcia-Rodriguez C, Farr-Jones S, Marks JD

Show all (209 more) Hide

• Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F.
  PloS one 2022 Fan Y, Sun Z, Conrad F, Wen W, Zhao L, Lou J, Zhou Y, Farr-Jones S, Marks JD
• Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model.
  Toxins 2021 Tomic MT, Farr-Jones S, Syar ES, Niemuth N, Kobs D, Hackett MJ, Espinoza Y, Martinez Z, Pham K, Snow DM, Marks JD, Cobb RR
• A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D.
  Toxins 2021 Garcia-Rodriguez C, Yan S, Geren IN, Knopp KA, Dong J, Sun Z, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD
• A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model.
  Toxins 2021 Snow DM, Cobb RR, Martinez J, Finger-Baker I, Collins L, Terpening S, Syar ES, Niemuth N, Kobs D, Barnewall R, Farr-Jones S, Marks JD, Tomic MT
• Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic.
  Pharmaceutics 2020 Kamoun W, Swindell E, Pien C, Luus L, Cain J, Pham M, Kandela I, Huang ZR, Tipparaju SK, Koshkaryev A, Askoxylakis V, Kirpotin DB, Bloom T, Mino-Kenudson M, Marks JD, Zalutskaya A, Bshara W, Morrison …
• Cryo-EM Reveals Integrin-Mediated TGF-β Activation without Release from Latent TGF-β.
  Cell 2020 Campbell MG, Cormier A, Ito S, Seed RI, Bondesson AJ, Lou J, Marks JD, Baron JL, Cheng Y, Nishimura SL
• The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA.
  Toxins 2019 Fan Y, Barash JR, Conrad F, Lou J, Tam C, Cheng LW, Arnon SS, Marks JD
• Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity.
  Science translational medicine 2019 Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, …
• Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination Against Botulinum C and D Neurotoxins.
  Antimicrobial agents and chemotherapy 2019 Snow DM, Riling K, Kimbler A, Espinoza Y, Wong D, Pham K, Martinez Z, Kraus CN, Conrad F, Garcia-Rodriguez C, Cobb RR, Marks JD, Tomic MT
• Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats.
  Toxins 2019 Espinoza Y, Wong D, Ahene A, Der K, Martinez Z, Pham J, Cobb RR, Farr-Jones S, Marks JD, Tomic MT
• Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model.
  Toxins 2019 Tomic MT, Espinoza Y, Martinez Z, Pham K, Cobb RR, Snow DM, Earnhart CG, Pals T, Syar ES, Niemuth N, Kobs DJ, Farr-Jones S, Marks JD
• Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.
  Nature biomedical engineering 2019 Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, …
• Botulinum Neurotoxins (BoNTs)-Antibody and Vaccine.
  Toxins 2018 Lou J, Marks JD
• Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.
  JCI insight 2018 Takasaka N, Seed RI, Cormier A, Bondesson AJ, Lou J, Elattma A, Ito S, Yanagisawa H, Hashimoto M, Ma R, Levine MD, Publicover J, Potts R, Jespersen JM, Campbell MG, Conrad F, Marks JD, Cheng Y, Baron …
• Antibody engineering to improve manufacturability.
  Protein expression and purification 2018 Wijesuriya SD, Pongo E, Tomic M, Zhang F, Garcia-Rodriquez C, Conrad F, Farr-Jones S, Marks JD, Horwitz AH
• A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes.
  Toxins 2018 Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD
• A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.
  Toxins 2018 Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD
• Discovery of internalizing antibodies to basal breast cancer cells.
  Protein engineering, design & selection : PEDS 2018 Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD
• A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes.
  PloS one 2017 Fan Y, Garcia-Rodriguez C, Lou J, Wen W, Conrad F, Zhai W, Smith TJ, Smith LA, Marks JD
• Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting.
  mAbs 2016 Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks JD, Drummond DC, Lugovskoy AA
• White Matter Injury and General Movements in High-Risk Preterm Infants.
  AJNR. American journal of neuroradiology 2016 Peyton C, Yang E, Msall ME, Adde L, Støen R, Fjørtoft T, Bos AF, Einspieler C, Zhou Y, Schreiber MD, Marks JD, Drobyshevsky A
• Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
  The Journal of infectious diseases 2016 Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS
• Development and Implementation of Checklists for Routine Anesthesia Care: A Proposal for Improving Patient Safety.
  Anesthesia and analgesia 2015 Krombach JW, Marks JD, Dubowitz G, Radke OC
• Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.
  Molecular cancer therapeutics 2015 Le Gall M, Crépin R, Neiveyans M, Auclair C, Fan Y, Zhou Y, Marks JD, Pèlegrin A, Poul MA
• Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.
  Toxins 2015 Fan Y, Dong J, Lou J, Wen W, Conrad F, Geren IN, Garcia-Rodriguez C, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD
• Checklists and Other Cognitive Aids For Emergency And Routine Anesthesia Care-A Survey on the Perception of Anesthesia Providers From a Large Academic US Institution.
  Anesthesiology and pain medicine 2015 Krombach JW, Edwards WA, Marks JD, Radke OC
• Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.
  Leukemia 2015 Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY, Marks JD, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF…
• Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity.
  PloS one 2015 Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD
• TGF-β-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease.
  Journal of immunology (Baltimore, Md. : 1950) 2015 Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Ma R, Murray LA, Tsui P, Lou J, Marks JD, Baron JL, Krummel MF, Nishimura SL
• A fully human scFv phage display library for rapid antibody fragment reformatting.
  Protein engineering, design & selection : PEDS 2015 Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM
• Transforming Growth Factor-β and Interleukin-1β Signaling Pathways Converge on the Chemokine CCL20 Promoter.
  The Journal of biological chemistry 2015 Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL
• Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.
  PloS one 2014 D'Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks JD, Litwin S, Robinson MK
• High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display.
  PloS one 2014 Zhao L, Qu L, Zhou J, Sun Z, Zou H, Chen YY, Marks JD, Zhou Y
• Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments.
  Molecular cancer therapeutics 2014 Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM
• Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins.
  The Analyst 2014 Jenko KL, Zhang Y, Kostenko Y, Fan Y, Garcia-Rodriguez C, Lou J, Marks JD, Varnum SM
• Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation.
  Protein engineering, design & selection : PEDS 2014 Tavaré R, Wu WH, Zettlitz KA, Salazar FB, McCabe KE, Marks JD, Wu AM
• Selective targeting of TGF-β activation to treat fibroinflammatory airway disease.
  Science translational medicine 2014 Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ…
• Identifying blood-brain-barrier selective single-chain antibody fragments.
  Biotechnology journal 2014 Jones AR, Stutz CC, Zhou Y, Marks JD, Shusta EV
• Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.
  FEBS letters 2014 Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A
• RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin.
  Talanta 2013 Janardhanan P, Mello CM, Singh BR, Lou J, Marks JD, Cai S
• Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E.
  The Biochemical journal 2013 Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T
• Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism.
  Journal of medical microbiology 2013 Jones RGA, Marks JD
• Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor.
  Sarcoma 2012 Federman N, Chan J, Nagy JO, Landaw EM, McCabe K, Wu AM, Triche T, Kang H, Liu B, Marks JD, Denny CT
• Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays.
  Analytical biochemistry 2012 Zhang Y, Lou J, Jenko KL, Marks JD, Varnum SM
• Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein.
  Analytical biochemistry 2012 Meng Q, Garcia-Rodriguez C, Manzanarez G, Silberg MA, Conrad F, Bettencourt J, Pan X, Breece T, To R, Li M, Lee D, Thorner L, Tomic MT, Marks JD
• N-Terminal labeling of filamentous phage to create cancer marker imaging agents.
  ACS nano 2012 Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks JD, Chokhawala H, Clark DS, Francis MB
• An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.
  Molecular imaging and biology 2012 McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM
• Selection and characterization of cell binding and internalizing phage antibodies.
  Archives of biochemistry and biophysics 2012 Zhou Y, Zhao L, Marks JD
• Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
  Molecular cancer therapeutics 2012 Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD
• A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test.
  Analytical biochemistry 2012 Liu YY, Rigsby P, Sesardic D, Marks JD, Jones RG
• Building and characterizing antibody-targeted lipidic nanotherapeutics.
  Methods in enzymology 2012 Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC
• Discovery of internalizing antibodies to tumor antigens from phage libraries.
  Methods in enzymology 2012 Zhou Y, Marks JD
• Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
  Molecular cancer therapeutics 2011 Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG
• Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies.
  BMC biochemistry 2011 Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR
• Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.
  The Journal of biological chemistry 2011 Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SKH
• Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein.
  Analytical biochemistry 2011 Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, Cao L, Tomic MT, Marks JD
• Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β.
  The Journal of clinical investigation 2011 Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL
• Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes.
  Biotechnology and bioengineering 2011 Gray SA, Barr JR, Kalb SR, Marks JD, Baird CL, Cangelosi GA, Miller KD, Feldhaus MJ
• Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.
  Cancer research 2011 Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP
• Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK
• Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin.
  Protein engineering, design & selection : PEDS 2010 Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks JD
• Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens.
  Journal of molecular biology 2010 Zhou Y, Zou H, Zhang S, Marks JD
• Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS.
  PloS one 2010 Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR
• TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS.
  American journal of translational research 2010 Diaz L, Mao H, Zhou Y, Kohli M, Cassella J, Santos D, Fesseha Z, Weng K, Chen H, Bamba D, Marks JD, Goldblatt M, Kinch M
• Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas.
  Cancer research 2010 Crépin R, Goenaga AL, Jullienne B, Bougherara H, Legay C, Benihoud K, Marks JD, Poul MA
• An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.
  European journal of nuclear medicine and molecular imaging 2010 Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM
• Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating.
  Protein engineering, design & selection : PEDS 2010 Lou J, Geren I, Garcia-Rodriguez C, Forsyth CM, Wen W, Knopp K, Brown J, Smith T, Smith LA, Marks JD
• Tumor detection by imaging proteolytic activity.
  Cancer research 2010 Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS
• A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region.
  Journal of molecular biology 2010 Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD
• Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
  Cancer research 2009 Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG
• Development of a highly stable and targetable nanoliposomal formulation of topotecan.
  Journal of controlled release : official journal of the Controlled Release Society 2009 Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB
• Antibody protection against botulinum neurotoxin intoxication in mice.
  Infection and immunity 2009 Cheng LW, Stanker LH, Henderson TD, Lou J, Marks JD
• Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity.
  Analytical chemistry 2009 Ozanich RM, Bruckner-Lea CJ, Warner MG, Miller K, Antolick KC, Marks JD, Lou J, Grate JW
• Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies.
  Biosensors & bioelectronics 2009 Warner MG, Grate JW, Tyler A, Ozanich RM, Miller KD, Lou J, Marks JD, Bruckner-Lea CJ
• Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.
  PloS one 2009 Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR
• Renewable surface fluorescence sandwich immunoassay biosensor for rapid sensitive botulinum toxin detection in an automated fluidic format.
  The Analyst 2009 Grate JW, Warner MG, Ozanich RM, Miller KD, Colburn HA, Dockendorff B, Antolick KC, Anheier NC, Lind MA, Lou J, Marks JD, Bruckner-Lea CJ
• Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.
  Journal of molecular medicine (Berlin, Germany) 2009 Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks JD, Liu B
• Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.
  Cancer chemotherapy and pharmacology 2009 Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC
• Identification of target and function specific antibodies for effective drug delivery.
  Methods in molecular biology (Clifton, N.J.) 2009 Zhou Y, Marks JD
• Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?
  Methods in molecular biology (Clifton, N.J.) 2009 Dimitrov DS, Marks JD
• Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, Fu M, Wu AM, Marks JD, Braun J, Gordon LK, Wadehra M
• Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.
  British journal of cancer 2008 Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP
• Development of human single-chain antibodies against SARS-associated coronavirus.
  Intervirology 2008 Leung KM, Feng DX, Lou J, Zhou Y, Fung KP, Waye MM, Tsui SK, Chan PK, Marks JD, Pang SF, Kan YW
• Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP
• Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids.
  PloS one 2007 Smith TJ, Hill KK, Foley BT, Detter JC, Munk AC, Bruce DC, Doggett NA, Smith LA, Marks JD, Xie G, Brettin TS
• Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy.
  The Journal of biological chemistry 2007 Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, Nakagawa T, Montal M
• Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.
  Molecular cancer therapeutics 2007 Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B
• Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.
  Journal of immunotherapy (Hagerstown, Md. : 1997) 2007 Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, Canevari S, Mezzanzanica D
• Affinity thresholds for membrane fusion triggering by viral glycoproteins.
  Journal of virology 2007 Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng KW
• Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
  Journal of immunology (Baltimore, Md. : 1950) 2007 Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM
• Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.
  Journal of molecular medicine (Berlin, Germany) 2007 Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD
• Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.
  Molecular immunology 2007 Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA
• Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
  Journal of molecular biology 2007 Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD
• Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.
  Nature biotechnology 2006 Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD
• Genetic diversity among Botulinum Neurotoxin-producing clostridial strains.
  Journal of bacteriology 2006 Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks JD
• Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation.
  Molecular pharmaceutics 2006 Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, C O N, Park JW, Marks JD, Benz CC, Kirpotin DB
• Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
  Journal of molecular biology 2006 Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD
• A novel assay for monitoring internalization of nanocarrier coupled antibodies.
  BMC immunology 2006 Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD
• Using phage display to select antibodies recognizing post-translational modifications independently of sequence context.
  Molecular & cellular proteomics : MCP 2006 Kehoe JW, Velappan N, Walbolt M, Rasmussen J, King D, Lou J, Knopp K, Pavlik P, Marks JD, Bertozzi CR, Bradbury AR
• A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4.
  Journal of molecular biology 2006 Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD, Johnson EA, Stevens RC
• Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
  Cancer research 2006 Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW
• Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies.
  Analytica chimica acta 2006 Varnum SM, Warner MG, Dockendorff B, Anheier NC, Lou J, Marks JD, Smith LA, Feldhaus MJ, Grate JW, Bruckner-Lea CJ
• Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases.
  Biochimica et biophysica acta 2006 Hayes ME, Drummond DC, Hong K, Park JW, Marks JD, Kirpotin DB
• Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery.
  Gene therapy 2006 Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, Marks JD, Benz CC, Hong K
• Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF, Houston LL, Huston JS, Weiner LM
• Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
  Cancer biotherapy & radiopharmaceuticals 2005 Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD
• Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
  Infection and immunity 2005 Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD
• Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A.
  Journal of molecular biology 2005 Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD
• Infectious Disease and Bioterrorism.
  Anesthesiology clinics of North America 2005 Hughes SC, Marks JD
• Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.
  Cancer research 2005 Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP
• Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification.
  Biotechnology progress 2005 Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, Giardina SL
• Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis.
  Biotechnology progress 2005 Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB
• Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42.
  Neurobiology of disease 2004 Manoutcharian K, Acero G, Munguia ME, Becerril B, Massieu L, Govezensky T, Ortiz E, Marks JD, Cao C, Ugen K, Gevorkian G
• A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.
  Cancer research 2004 Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM
• Medical aspects of biologic toxins.
  Anesthesiology clinics of North America 2004 Marks JD
• Development of ligand-targeted liposomes for cancer therapy.
  Expert opinion on therapeutic targets 2004 Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC
• Antibodies from phage antibody libraries.
  Journal of immunological methods 2004 Bradbury AR, Marks JD
• Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies.
  Journal of immunological methods 2004 Hall YH, Chaddock JA, Moulsdale HJ, Kirby ER, Alexander FC, Marks JD, Foster KA
• Yeast mating for combinatorial Fab library generation and surface display.
  FEBS letters 2004 Weaver-Feldhaus JM, Lou J, Coleman JR, Siegel RW, Marks JD, Feldhaus MJ
• Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.
  Movement disorders : official journal of the Movement Disorder Society 2004 Marks JD
• Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron.
  Journal of immunological methods 2004 Secco P, Ferretti M, Gioia D, Cesaro P, Bozzo C, Marks JD, Santoro C
• Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells.
  Cancer research 2004 Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD
• Antibody affinity maturation by chain shuffling.
  Methods in molecular biology (Clifton, N.J.) 2004 Marks JD
• PCR cloning of human immunoglobulin genes.
  Methods in molecular biology (Clifton, N.J.) 2004 Marks JD, Bradbury A
• Selection of human antibodies from phage display libraries.
  Methods in molecular biology (Clifton, N.J.) 2004 Marks JD, Bradbury A
• Selection of internalizing antibodies for drug delivery.
  Methods in molecular biology (Clifton, N.J.) 2004 Marks JD
• Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
  Cancer research 2003 Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW
• Predicting antigenic peptides suitable for the selection of phage antibodies.
  Human antibodies 2003 Pavlik P, Siegel RW, Marzari R, Sblattero D, Verzillo V, Collins C, Marks JD, Bradbury A
• The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies.
  European journal of immunology 2002 Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, Marks JD, Bradbury A, Tedesco F
• Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.
  Biochimica et biophysica acta 2002 Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD
• Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.
  Proceedings of the National Academy of Sciences of the United States of America 2002 Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD
• Phage versus phagemid libraries for generation of human monoclonal antibodies.
  Journal of molecular biology 2002 O'Connell D, Becerril B, Roy-Burman A, Daws M, Marks JD
• Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.
  The Journal of infectious diseases 2002 Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T
• Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2002 Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC
• The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies.
  Journal of molecular biology 2002 Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A
• Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.
  Vaccine 2002 Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD
• Phage-display antibody detection of Chlamydia trachomatis-associated antigens.
  Microbiology (Reading, England) 2002 Lindquist EA, Marks JD, Kleba BJ, Stephens RS
• Towards proteome-wide production of monoclonal antibody by phage display.
  Journal of molecular biology 2002 Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD
• Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.
  Infection and immunity 2001 Mullaney BP, Pallavicini MG, Marks JD
• Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells.
  Cancer gene therapy 2001 Li X, Stuckert P, Bosch I, Marks JD, Marasco WA
• Tumor targeting using anti-her2 immunoliposomes.
  Journal of controlled release : official journal of the Controlled Release Society 2001 Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC
• High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
  Cancer research 2001 Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM
• Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity.
  Journal of immunology (Baltimore, Md. : 1950) 2001 McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM
• Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin.
  Toxicon : official journal of the International Society on Toxinology 2001 Sheridan RE, Deshpande SS, Amersdorfer P, Marks JD, Smith T
• Expression of single-chain Fv-Fc fusions in Pichia pastoris.
  Journal of immunological methods 2001 Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD
• Antibodies to human fetal erythroid cells from a nonimmune phage antibody library.
  Proceedings of the National Academy of Sciences of the United States of America 2001 Huie MA, Cheung MC, Muench MO, Becerril B, Kan YW, Marks JD
• Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library.
  Journal of immunological methods 2001 Heitner T, Moor A, Garrison JL, Marks C, Hasan T, Marks JD
• Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.
  Biochemical and biophysical research communications 2001 Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC
• Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells.
  Journal of immunotherapy (Hagerstown, Md. : 1997) 2001 Marshall KW, Marks JD
• Lung collapse during low tidal volume ventilation in acute respiratory distress syndrome.
  Respiratory care 2001 Kallet RH, Siobal MS, Alonso JA, Warnecke EL, Katz JA, Marks JD
• Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
  Cancer research 2000 Nielsen UB, Adams GP, Weiner LM, Marks JD
• Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose.
  Analytical biochemistry 2000 Liu B, Marks JD
• Mass spectral analysis of a protein complex using single-chain antibodies selected on a peptide target: applications to functional genomics.
  Journal of molecular biology 2000 Siegel RW, Allen B, Pavlik P, Marks JD, Bradbury A
• Measuring intra-esophageal pressure to assess transmural pulmonary arterial occlusion pressure in patients with acute lung injury: a case series and review.
  Respiratory care 2000 Kallet RH, Katz JA, Pittet JF, Ghermey J, Siobal M, Alonso JA, Marks JD
• Selection of tumor-specific internalizing human antibodies from phage libraries.
  Journal of molecular biology 2000 Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD
• Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules.
  Nuclear medicine and biology 2000 Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW
• The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM).
  American journal of respiratory and critical care medicine 2000 Kallet RH, Jasmer RM, Luce JM, Lin LH, Marks JD
• Improved flow and pressure capabilities of the Datex-Ohmeda SmartVent anesthesia ventilator.
  Journal of clinical anesthesia 2000 Katz JA, Kallet RH, Alonso JA, Marks JD
• Initial severity of metabolic acidosis predicts the development of acute lung injury in severely traumatized patients.
  Critical care medicine 2000 Eberhard LW, Morabito DJ, Matthay MA, Mackersie RC, Campbell AR, Marks JD, Alonso JA, Pittet JF
• Phage libraries for generation of anti-botulinum scFv antibodies.
  Methods in molecular biology (Clifton, N.J.) 2000 Amersdorfer P, Marks JD
• Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.
  Infection and immunity 1999 Cirino NM, Sblattero D, Allen D, Peterson SR, Marks JD, Jackson PJ, Bradbury A, Lehnert BE
• Synthesis of Rh Fv phage-antibodies using VH and VL germline genes.
  British journal of haematology 1999 Hughes-Jones NC, Bye JM, Gorick BD, Marks JD, Ouwehand WH
• Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
  Molecular immunology 1999 McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM
• Targeted gene delivery to mammalian cells by filamentous bacteriophage.
  Journal of molecular biology 1999 Poul MA, Marks JD
• Toward selection of internalizing antibodies from phage libraries.
  Biochemical and biophysical research communications 1999 Becerril B, Poul MA, Marks JD
• Characterization of anti-mouse Fc gamma RII single-chain Fv fragments derived from human phage display libraries.
  Immunotechnology : an international journal of immunological engineering 1998 McCall AM, Amoroso AR, Sautès C, Marks JD, Weiner LM
• Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens.
  Proceedings of the National Academy of Sciences of the United States of America 1998 Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, Hemingsen G, Wong C, Gerhart JC, Marks JD, Lindqvist E
• Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
  British journal of cancer 1998 Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD
• Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
  Critical care medicine 1998 Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD
• Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
  Cancer research 1998 Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM
• Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.
  Infection and immunity 1997 Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD
• Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms.
  Infection and immunity 1997 Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks JD, Stevens RC
• Human autoimmune anti-proteinase 3 scFv from a phage display library.
  Clinical and experimental immunology 1997 Finnern R, Pedrollo E, Fisch I, Wieslander J, Marks JD, Lockwood CM, Ouwehand WH
• Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
  Journal of molecular biology 1996 Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD
• Phage libraries--a new route to clinically useful antibodies.
  The New England journal of medicine 1996 Marks C, Marks JD
• Identification of functional and structural amino-acid residues by parsimonious mutagenesis.
  Gene 1996 Schier R, Balint RF, McCall A, Apell G, Larrick JW, Marks JD
• Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.
  Journal of molecular biology 1996 Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD
• Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections.
  Human antibodies and hybridomas 1996 Schier R, Marks JD
• Molecular characteristics of anti-self antibody fragments against neutrophil cytoplasmic antigens from human V gene phage display libraries.
  Clinical and experimental immunology 1995 Finnern R, Bye JM, Dolman KM, Zhao MH, Short A, Marks JD, Lockwood MC, Ouwehand WH
• In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library.
  Immunotechnology : an international journal of immunological engineering 1995 Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM
• Characterization of human blood group scFv antibodies derived from a V gene phage-display library.
  British journal of haematology 1994 Hughes-Jones NC, Gorick BD, Bye JM, Finnern R, Scott ML, Voak D, Marks JD, Ouwehand WH
• In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation.
  Journal of molecular biology 1994 Figini M, Marks JD, Winter G, Griffiths AD
• Fiberoptic-aided endobronchial intubation.
  International anesthesiology clinics 1994 Marks JD
• Performing fiberoptic endotracheal intubation: clinical aspects.
  International anesthesiology clinics 1994 Stackhouse RA, Marks JD, Bainton CR
• Practical aspects of fiberoptic laryngobronchoscopy.
  International anesthesiology clinics 1994 Marks JD, Bainton CR
• The humoral immune response against blood group antigens at the molecular level.
  Vox sanguinis 1994 Ouwehand WH, Bye JM, Gorick BD, Marks JD, Timmers E, Griffin HM, Finnern R, Hughes-Jones N
• Human antibody fragments specific for human blood group antigens from a phage display library.
  Bio/technology (Nature Publishing Company) 1993 Marks JD, Ouwehand WH, Bye JM, Finnern R, Gorick BD, Voak D, Thorpe SJ, Hughes-Jones NC, Winter G
• Human anti-self antibodies with high specificity from phage display libraries.
  The EMBO journal 1993 Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, Baier M, Holliger KP, Gorick BD, Hughes-Jones NC
• Building antibodies from their genes.
  Immunological reviews 1992 Hoogenboom HR, Marks JD, Griffiths AD, Winter G
• Germline variable region gene segment derivation of human monoclonal anti-Rh(D) antibodies. Evidence for affinity maturation by somatic hypermutation and repertoire shift.
  The Journal of clinical investigation 1992 Bye JM, Carter C, Cui Y, Gorick BD, Songsivilai S, Winter G, Hughes-Jones NC, Marks JD
• Structural repertoire of the human VH segments.
  Journal of molecular biology 1992 Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G
• The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops.
  Journal of molecular biology 1992 Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G
• Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system.
  The Journal of biological chemistry 1992 Marks JD, Hoogenboom HR, Griffiths AD, Winter G
• By-passing immunization: building high affinity human antibodies by chain shuffling.
  Bio/technology (Nature Publishing Company) 1992 Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G
• An artificial immune system for making antibodies.
  Behring Institute Mitteilungen 1992 Marks JD, Winter G
• By-passing immunization. Human antibodies from V-gene libraries displayed on phage.
  Journal of molecular biology 1991 Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G
• Airway management for trauma patients with potential cervical spine injuries.
  Anesthesia and analgesia 1991 Hastings RH, Marks JD
• Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes.
  European journal of immunology 1991 Marks JD, Tristem M, Karpas A, Winter G
• Cloning and sequencing of human lambda immunoglobulin genes by the polymerase chain reaction.
  European journal of immunology 1990 Songsivilai S, Bye JM, Marks JD, Hughes-Jones NC
• Factors affecting perioperative pulmonary function in acute respiratory failure.
  Chest 1990 Biery DR, Marks JD, Schapera A, Autry M, Schlobohm RM, Katz JA
• Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome.
  The Journal of clinical investigation 1990 Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Luce JM, Montgomery AB, Marks JD, Matthay MA
• Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration.
  The American review of respiratory disease 1990 Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF
• Perioperative pulmonary function in acute respiratory failure: effect of ventilator type and gas mixture.
  Anesthesiology 1989 Schapera A, Marks JD, Minagi H, Goodman P, Katz JA
• Pressure and flow limitations of anesthesia ventilators.
  Anesthesiology 1989 Marks JD, Schapera A, Kraemer RW, Katz JA
• Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock.
  The American review of respiratory disease 1988 Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF
• Poor correlation between pulmonary arterial wedge pressure and left ventricular end-diastolic volume after coronary artery bypass graft surgery.
  Anesthesiology 1986 Hansen RM, Viquerat CE, Matthay MA, Wiener-Kronish JP, DeMarco T, Bahtia S, Marks JD, Botvinick EH, Chatterjee K
• Inspiratory work with and without continuous positive airway pressure in patients with acute respiratory failure.
  Anesthesiology 1985 Katz JA, Marks JD
• Effect of increases in lung volume on clearance of aerosolized solute from human lungs.
  Journal of applied physiology (Bethesda, Md. : 1985) 1985 Marks JD, Luce JM, Lazar NM, Wu JN, Lipavsky A, Murray JF
• The inhibitory action of a phenothiazine derivative on the hexosemonophosphate dehydrogenases of adrenal cortex.
  Archives of biochemistry and biophysics 1961 MARKS JD, ROESKY N, CARVER MJ